Treatment for Active TB vs Latent TB
For active tuberculosis, use a 2-month intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol, followed by a 4-month continuation phase of isoniazid and rifampin; for latent tuberculosis infection, use 3 months of once-weekly isoniazid plus rifapentine as the preferred regimen. 1, 2
Active Tuberculosis Treatment
Standard Regimen for Drug-Susceptible TB
The treatment consists of two distinct phases 1:
Intensive Phase (2 months):
- Isoniazid (INH)
- Rifampin (RIF)
- Pyrazinamide (PZA)
- Ethambutol (EMB)
Continuation Phase (4 months):
- Isoniazid (INH)
- Rifampin (RIF)
Key Modifications
Ethambutol can be discontinued once drug susceptibility testing confirms the organism is susceptible to both isoniazid and rifampin. If susceptibility is known before starting treatment, the intensive phase can consist of only INH, RIF, and PZA 1.
Extended continuation phase (7 months total) is required for patients with cavitation on initial chest radiograph AND positive cultures at completion of 2 months of therapy 1.
Essential Adjunctive Therapy
Pyridoxine (vitamin B6) 25-50 mg daily must be given with isoniazid to all persons at risk of neuropathy, including 1:
- Pregnant women
- Breastfeeding infants
- Persons with HIV
- Patients with diabetes, alcoholism, malnutrition, or chronic renal failure
- Patients of advanced age
For patients who develop peripheral neuropathy, increase pyridoxine to 100 mg daily 1.
Administration Schedule
Daily dosing is preferred for both phases. While 5-days-per-week administration via directly observed therapy (DOT) has not been compared to 7-day administration in clinical trials, extensive clinical experience supports this as an acceptable alternative 1.
DOT is the standard of care for pulmonary TB and should be used when drugs are administered less than 7 days per week 1, 3.
Latent Tuberculosis Infection (LTBI) Treatment
Preferred Regimens (in priority order) 2
1. Three months of isoniazid plus rifapentine once weekly (3HP)
- Strong recommendation with moderate evidence
- Highest completion rates due to shorter duration
- Excellent tolerability and efficacy
2. Four months of daily rifampin (4R)
- Strong recommendation with moderate evidence for HIV-negative persons
- No evidence reported in HIV-positive persons
3. Three months of daily isoniazid plus rifampin (3HR)
- Conditional recommendation with very low evidence for HIV-negative persons
- Conditional recommendation with low evidence for HIV-positive persons
- Hepatotoxicity risk may be greater with two drugs together than either alone 2
Alternative Regimens 2
Six months of daily isoniazid (6H)
- Strong recommendation for HIV-negative adults and children
- Conditional recommendation for HIV-positive persons
Nine months of daily isoniazid (9H)
- Conditional recommendation for all adults and children, both HIV-negative and HIV-positive
- Historically the standard regimen but now alternative due to longer duration and lower completion rates
Critical Caveat
Active tuberculosis must be ruled out before initiating LTBI treatment through patient history, physical examination, and chest radiography 4. If active TB is not adequately excluded, there is risk of acquired drug resistance with shorter LTBI regimens 2.
Special Populations
HIV-positive persons with negative TST, anergy, or unknown TST: The benefit of isoniazid is uncertain in low TB incidence settings. However, in high TB incidence areas, isoniazid plus antiretroviral therapy decreases TB disease incidence more than either intervention alone 2.
Persons with inactive TB (fibrotic lesions): Six to 12-24 months of isoniazid therapy is more effective than 2-3 months, demonstrating particular benefit in this high-risk subset 2.
Key Distinctions Between Active and Latent TB Treatment
| Feature | Active TB | Latent TB |
|---|---|---|
| Duration | 6 months minimum (up to 9 months with cavitation) | 3-9 months depending on regimen |
| Number of drugs | 4 drugs initially, then 2 drugs | 1-2 drugs |
| DOT requirement | Standard of care [1] | Recommended for once-weekly regimens |
| Goal | Cure active disease, prevent transmission | Prevent progression to active disease |
| Monitoring intensity | Intensive with culture follow-up | Less intensive, primarily for adverse effects |
The fundamental difference is that active TB requires multi-drug therapy to address the large bacterial burden and prevent resistance, while LTBI treatment targets a smaller bacterial population with lower risk of resistance development, allowing for shorter, simpler regimens.